The UK-based company's revenues are generated exclusively from epigenetic biomarker research and development alliances with commercial and academic partners.
Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.
Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.
